Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a Waltham, Massachusetts-based biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. News about Viridian often centers on its late-stage programs in thyroid eye disease (TED), regulatory milestones, clinical trial updates, and financing activities that support its pipeline and anticipated commercialization efforts.
Investors following VRDN news can expect frequent updates on veligrotug, Viridian’s intravenously delivered anti–IGF‑1R antibody for TED. Company announcements have highlighted the completion of two global phase 3 trials, THRIVE and THRIVE‑2, positive topline data, and the U.S. Food and Drug Administration’s acceptance of a Biologics License Application with Priority Review and a defined PDUFA target action date. News releases also discuss preparations for a potential commercial launch, including market access, medical affairs, and engagement with a core prescriber base.
Another key news theme is VRDN‑003 (elegrobart), a subcutaneous, half‑life extended anti‑IGF‑1R antibody in phase 3 trials REVEAL‑1 and REVEAL‑2 for active and chronic TED. Viridian’s press releases describe enrollment progress, anticipated topline data timing, and the design of VRDN‑003 for subcutaneous administration in a low‑volume autoinjector with every‑four‑week or every‑eight‑week dosing. Updates on Viridian’s FcRn inhibitor portfolio—including VRDN‑006 and VRDN‑008—cover proof‑of‑concept IgG reduction data, investigational new drug (IND) submissions, and preclinical head‑to‑head findings.
VRDN news also frequently includes corporate and financial developments, such as public equity offerings, royalty financing agreements, amended credit facilities, and collaboration and license agreements like the partnership with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. These disclosures provide context on how Viridian plans to fund its clinical programs and potential commercial launches. For a comprehensive view of Viridian’s evolving TED pipeline, autoimmune disease programs, and capital strategy, readers can review the ongoing stream of press releases, earnings updates, and SEC-reported events associated with the VRDN ticker.
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company focused on developing potential best-in-class medicines for serious and rare diseases, has announced the approval of inducement grants for two new employees. The grants, approved by the Compensation Committee of the company's Board of Directors, consist of non-qualified stock options to purchase 19,500 shares of Viridian's common stock.
These grants, made on August 1, 2024, are outside the company's Amended and Restated 2016 Equity Incentive Plan but remain subject to its terms. The options have an exercise price equal to the closing price of Viridian's stock on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, contingent on continued employment.
Viridian Therapeutics (NASDAQ: VRDN) has completed enrollment for its THRIVE-2 phase 3 clinical trial of VRDN-001 in patients with chronic Thyroid Eye Disease (TED). The trial exceeded its target, enrolling 188 patients globally, with about 40% from US sites. Topline data from THRIVE-2 is expected by year-end 2024.
The company's THRIVE trial for active TED also surpassed its enrollment goal in March 2024, with approximately 50% of patients from US sites. Topline results for THRIVE are anticipated in September 2024. Viridian plans to initiate two subcutaneous VRDN-003 phase 3 clinical trials, REVEAL-1 and REVEAL-2, in August as scheduled.
Viridian Therapeutics announced the approval of inducement grants for 10 new employees, totaling 538,000 shares of common stock, effective July 1, 2024. These grants, approved by the independent directors on the Compensation Committee, are issued outside the company’s 2016 Equity Incentive Plan but adhere to its terms. The grants, designed to attract new talent under Nasdaq Listing Rule 5635(c)(4), have an exercise price matching the stock’s closing price on the grant date. Vesting occurs over four years, with 25% vesting on the one-year employment anniversary and the remainder vesting in 36 equal monthly installments.
Viridian Therapeutics is set to launch two phase 3 clinical trials, REVEAL-1 and REVEAL-2, for their subcutaneous (SC) VRDN-003 product aimed at treating moderate-to-severe Thyroid Eye Disease (TED). The trials will begin in August 2024, with results expected in the first half of 2026. VRDN-003, an anti-IGF-1R antibody, offers a less burdensome dosing regimen compared to current treatments. The company plans to submit a Biologics License Application (BLA) by the end of 2026. If successful, VRDN-003 could become a best-in-class treatment option administered as infrequently as every 8 weeks.
Viridian Therapeutics announced that its Compensation Committee approved the grant of non-qualified stock options to purchase 450,000 shares of common stock to two new employees. These inducement grants, given outside the company's 2016 Equity Incentive Plan but adhering to its terms, were approved on June 3, 2024. The stock options' exercise price matches Viridian's closing stock price on the grant date. The grants will vest over four years, with 25% vesting after one year, and the remainder vesting monthly over the next three years, contingent upon continued employment.
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced its participation in two upcoming investor conferences in June 2024. The company's senior management will present at the Jefferies Global Healthcare Conference in New York on June 5 at 5:00 p.m. ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 11 at 8:40 a.m. ET. Live webcasts of each presentation will be available on the Viridian Therapeutics website, with replays accessible post-events.
Viridian Therapeutics, a biopharmaceutical company (NASDAQ: VRDN), will participate in investor conferences in May 2024. The company aims to present potential best-in-class medicines for serious and rare diseases at the RBCCM Global Healthcare Conference in New York and the BofA Securities Health Care Conference in Las Vegas.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported significant progress in their Thyroid Eye Disease and FcRn inhibitor programs, highlighting completion of the THRIVE VRDN-001 global phase 3 clinical trial for active TED, enrollment exceeding expectations. The company remains on track for key milestones, with a positive FDA meeting for VRDN-003 and IND submission for VRDN-006 expected by year-end 2024. Financially, cash position improved to $613.2 million with a net loss of $48.5 million for the first quarter of 2024.
Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for six new employees. The Inducement Grants were granted outside of the company's Equity Incentive Plan but are subject to its terms. The grants aim to attract new talent and were approved by independent directors. The options have an exercise price equal to the closing price of the company's common stock on the Grant Date and will vest over a four-year period.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will host a webcast to discuss its first quarter 2024 financial results and recent business highlights on May 8, 2024. The company focuses on discovering medicines for serious and rare diseases.